Refractory Desmoplastic Small Round Cell Tumors Completed Phase 1 / 2 Trials for Imatinib (DB00619)

IndicationStatusPhase
DBCOND0036222 (Refractory Desmoplastic Small Round Cell Tumors)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00417807Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell TumorsTreatment